Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from MHRA

Reporting of vaccine side-effects should be mandatory – Tory former minister

Esther McVey said there was a ‘gross underreporting’ of unintended impacts of vaccines to the medicines regulator.

The Independent UK

The big menopause swizz: do hormone supplements really work?

The global market for menopause products is worth £16.93bn, the majority of that spent on dietary supplements – but is there any evidence they do anything?

The Guardian - UK

Woman ‘suicidal’ after taking same antidepressants as Thomas Kingston issues warning over side effects

Coroner and MPs raise concerns as almost 200 alerts made in decade to regulator over deaths linked to drugs

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

‘Don’t buy weight-loss pills online without prescription after Christmas over-eating,’ Britons warned

The warning was issued by the UK’s medicines watchdog

Evening Standard

NHS delays may drive patients to buy unsafe weight-loss drugs, says top GP

People warned against buying illegal weight-loss medicines through beauty salons or fake pharmacy websites

The Guardian - UK

‘Wild west’: experts concerned by illegal promotion of weight-loss jabs in UK

Guardian review finds many online pharmacies flouting strict advertising rules that govern prescription-only drugs

The Guardian - UK

Shrinking waistlines and growing profits: the weight-loss drug boom

Drugs such as Wegovy amd Mounjaro are an attractive prospect for online businesses and traditional pharmacies as well as the firms that make them

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

More than 100 alerts over deaths linked to antidepressants taken by Thomas Kingston

The UK’s medicines regulator is reviewing safety alerts for 30 common antidepressants

The Independent UK

A common nasal decongestant lacks evidence but is still sold in the UK

For years, the drug phenylephrine has been a popular choice for relieving nasal congestion, however, the US Food and Drug Administration (FDA) is considering removing oral phenylephrine medicines from pharmacy shelves. Recent FDA findings suggest it lacks effectiveness.

The Conversation

Warning of future deaths risk after three babies who had contaminated feed died

Three premature babies received total parenteral nutrition feed, contaminated by Bacillus cereus, while undergoing care in hospital.

Evening Standard

The UK’s NHS to roll out free antismoking pill. Will it work?

The UK’s National Health Service hopes the drug will help reduce the cost of treating serious illnesses.

Al Jazeera

Alzheimer’s treatment donanemab is not a ‘miracle drug’ – not providing it on the NHS is the right choice

There was frustration in some corners of the media when it was announced that a new drug to slow the progression of Alzheimer’s was not going to be made available on the NHS.

The Conversation

Alzheimer’s drug approved in the UK, but it won’t be available on the NHS – here’s why

The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.

The Conversation

Doctors urged to look out for weight loss jab ‘misuse’

The medicines regulator has also urged medics to warn patients of side effects.

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Tens of thousands of UK dementia patients to be enrolled in clinical trials

News of the £20m scheme comes as new drug for Alzheimer’s was rejected for use on NHS in England

The Independent UK

New Alzheimer’s drug rejected for NHS use – because it’s not worth the money

Alzheimer’ patients in UK left behind over regulator’s decision to reject use of new drugs

Evening Standard

Donanemab – what we know about the latest Alzheimer’s drug

The drug is one of the new ‘disease modifying’ treatments for Alzheimer’s disease.

The Independent UK

Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

Alzheimer’s drug rejected for widespread use by NHS spending watchdog

Donanemab is a so-called disease-modifying treatment.

The Independent UK

What you need to know about lecanemab – the Alzheimer’s drug rejected for NHS use

The drug has been developed by Eisai, a Japanese pharmaceutical company, and is sold under the brand name Leqembi

Evening Standard

What is Lecanemab and who makes it? Alzheimer’s drug gets approval but will not be available on the NHS

NICE says drug is not cost effective and shares fears of side effects

The Independent UK

First drug to slow Alzheimer’s progression will not be made available on the NHS

The spending watchdog has recommended that a drug shown to slow the progression of Alzheimer’s disease should not be rolled out on the NHS.

The Guardian - UK

UK health regulator rejects lecanemab as treatment for Alzheimer’s

Decision by Nice to rule out drug being available on NHS comes despite medicines licensing body giving green light

The Independent UK

Weight-loss jab to be used to prevent other health problems

Some 17,600 people took part in the trial and were either prescribed Wegovy or a dummy drug

The Guardian - UK

UK needs Covid-style push on dementia drugs, says ex-head of vaccine taskforce

Kate Bingham says ageing population means tackling dementia must be treated as economic imperative

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.